Patent(s) and the Corresponding Patented Drug(s) |
Top |
World Intellectual Property Organization (WIPO) |
Patent ID |
WO2012135799 |
Title |
Substituted 3-(1H-Benzo{D}Imidazol-2-Yl)-1H-Indazole-Analogs As Inhibitors of The Pdk1 Kinase. |
Abstract |
In one aspect, the invention relates to substituted 3-(lH-benzo[d]imidazol-2-yl)-lH- indazole analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the PDK1 kinase; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions for treating disorders associated with dysfunction of the PDK1 kinase. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. |
Applicant(s) |
University of Utah Research Foundation |
Representative Drug(s) |
D0DC2P |
Drug Info
|
IC50 = 300 nM |
Click to Show More |
[1] |
2
|
D0R0SJ
|
Drug Info
|
IC50 = 780 nM
|
[1] |
Patent ID |
WO2012058176 |
Title |
Novel Heteroaryl-Carboxamide Derivatives As Pdk1 Inhibitors. |
Abstract |
This invention relates to certain Heteroaryl Carboxamide derivatives of Formula (I) as inhibitors of 3-phosphoinositide-dependent protein kinase (PDK-1). The compounds can be useful in inhibiting the proliferation of cancer cells, and other aberrant conditions where the PDK-1 signaling pathway is overstimulated. |
Applicant(s) |
Merck Sharp & Dohme Corp |
Representative Drug(s) |
D00LMA |
Drug Info
|
IC50 <= 50 nM |
Click to Show More |
[1] |
2
|
D00ZXR
|
Drug Info
|
IC50 <= 50 nM
|
[1] |
3
|
D03WFI
|
Drug Info
|
IC50 <= 50 nM
|
[1] |
4
|
D08SNT
|
Drug Info
|
IC50 <= 50 nM
|
[1] |
5
|
D0GH9W
|
Drug Info
|
IC50 <= 50 nM
|
[1] |
6
|
D0H7SO
|
Drug Info
|
IC50 <= 50 nM
|
[1] |
7
|
D0MG4D
|
Drug Info
|
IC50 <= 50 nM
|
[1] |
8
|
D0MW7L
|
Drug Info
|
IC50 <= 50 nM
|
[1] |
9
|
D0TB2H
|
Drug Info
|
IC50 <= 50 nM
|
[1] |
10
|
D0WT9J
|
Drug Info
|
IC50 <= 50 nM
|
[1] |
Patent ID |
WO2012058174 |
Title |
Novel Thiazole-Carboxamide Derivatives As Pdk1 Inhibitors. |
Abstract |
This invention relates to certain thiazole carboxamide derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase (PDK-1). The compounds can be useful in inhibiting the proliferation of cancer cells, and other aberrant conditions where the PDK-1 signaling pathway is overstimulated. |
Applicant(s) |
Merck Sharp & Dohme Corp |
Patent ID |
WO2012044157 |
Title |
Product Conveying Device for Lifting A Product From A Conveying Means. |
Abstract |
A product conveying device, comprising a substantially horizontally disposed conveying means (101) for supplying a product, a movable support (112) and a lifting mechanism (102) mounted on the movable support for lifting the product from the conveying means. The conveying means is provided with a plurality of slots (106) arranged in one direction and the lifting mechanism comprises support elements (103) that can cooperate with the slots. The movable support is designed for displacing the lifting mechanism, such that the support elements can be moved into the slots from above, wherein the support elements can be moved under the product in the direction in which the slots extend and wherein the product being supplied can subsequently be lifted from the conveying means by means of the support elements. |
Applicant(s) |
Beheersmaatschappij Gach.M. Jentjens Bv |
Representative Drug(s) |
D02USE |
Drug Info
|
IC50 = 100 to 5000 nM |
Click to Show More |
[1] |
2
|
D04BBT
|
Drug Info
|
IC50 = 100 to 5000 nM
|
[1] |
3
|
D04MHV
|
Drug Info
|
IC50 = 100 to 5000 nM
|
[1] |
4
|
D0EH9Z
|
Drug Info
|
IC50 = 100 to 5000 nM
|
[1] |
5
|
D0FW3M
|
Drug Info
|
IC50 = 100 to 5000 nM
|
[1] |
6
|
D0HI8X
|
Drug Info
|
IC50 = 100 to 5000 nM
|
[1] |
7
|
D0RH6G
|
Drug Info
|
IC50 = 100 to 5000 nM
|
[1] |
8
|
D0WX4H
|
Drug Info
|
IC50 = 100 to 5000 nM
|
[1] |
Patent ID |
WO2012036974 |
Title |
Novel Thiazol-Carboximide Derivatives As Pdk1 Inhibitors. |
Abstract |
This invention relates to certain thiazole carboxamide derivatives of Formula (I) as inhibitors of 3-phosphoinositide-dependent protein kinase (PDK-1). The compounds can be useful in inhibiting the proliferation of cancer cells, and other aberrant conditions where the PDK-1 signaling pathway is overstimulated. |
Applicant(s) |
Merck Sharp & Dohme Corp |
Representative Drug(s) |
D0JR0F |
Drug Info
|
IC50 < 50 nM |
Click to Show More |
[1] |
2
|
D0Z3HW
|
Drug Info
|
IC50 = 100 nM
|
[1] |
3
|
D04BBA
|
Drug Info
|
IC50 < 250 nM
|
[1] |
4
|
D04QRX
|
Drug Info
|
IC50 < 250 nM
|
[1] |
5
|
D07ZMG
|
Drug Info
|
IC50 < 250 nM
|
[1] |
6
|
D0B2GM
|
Drug Info
|
IC50 < 250 nM
|
[1] |
7
|
D0D8PF
|
Drug Info
|
IC50 < 250 nM
|
[1] |
8
|
D0DO6K
|
Drug Info
|
IC50 < 250 nM
|
[1] |
9
|
D0FJ4A
|
Drug Info
|
IC50 < 250 nM
|
[1] |
10
|
D0GE6F
|
Drug Info
|
IC50 < 250 nM
|
[1] |
11
|
D0GY8G
|
Drug Info
|
IC50 < 250 nM
|
[1] |
12
|
D0KN7T
|
Drug Info
|
IC50 < 250 nM
|
[1] |
13
|
D0P6PT
|
Drug Info
|
IC50 < 250 nM
|
[1] |
14
|
D0QV1E
|
Drug Info
|
IC50 < 250 nM
|
[1] |
15
|
D0U7LW
|
Drug Info
|
IC50 < 250 nM
|
[1] |
Patent ID |
WO2011137219 |
Title |
Inhibitors of Phosphoinositide Dependent Kinase 1 (Pdk1). |
Abstract |
The instant invention provides for compounds that inhibit PDK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting PDK1 activity by administering the compound to a patient in need of treatment of cancer. |
Applicant(s) |
Merck Sharp & Dohme Corp |
Representative Drug(s) |
D0P0WF |
Drug Info
|
IC50 = 33 nM |
Click to Show More |
[1] |
2
|
D0IO2X
|
Drug Info
|
IC50 = 85 nM
|
[1] |
3
|
D00SVK
|
Drug Info
|
IC50 = 110 nM
|
[1] |
4
|
D0B8OB
|
Drug Info
|
IC50 = 170 nM
|
[1] |
Patent ID |
WO2006106326 |
Title |
Substituted Heterocycles and Their Use As Chk1, Pdk1 and Pak Inhibitors. |
Abstract |
This invention relates to novel compounds of Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds possess CHK1 kinase inhibitory activity, PDK1 inhibitory activity and Pak kinase inhibitory activity and are accordingly useful in the treatment and/or prophylaxis of cancer. |
Applicant(s) |
Astrazeneca Ab |
Representative Drug(s) |
D03GFZ |
Drug Info
|
IC50 = 160 nM |
Click to Show More |
[1] |
2
|
D06BSG
|
Drug Info
|
IC50 = 350 nM
|
[1] |
Patent ID |
WO2012072200 |
Title |
3-Hetaryl-Substituted Pyrrolo[2,3-B]Pyridine Derivatives As Pdk1 Inhibitors. |
Abstract |
Compounds of the formula I in which Q, R1, R2, R3 and R4 are each as defined in claim 1 are PDK1 inhibitors and can be used for treatment of tumors. |
Applicant(s) |
Merck Patent Gmbh |
Patent ID |
WO2011076327 |
Title |
Pyrrolo[2,3-D]Pyrazin-7-Yl Pyrimidine Compounds. |
Abstract |
The invention relates to pyrrolo[2,3-d]pyrazin-7-yl pyrimidine compounds that are cell proliferation/cell vitality inhibitors and can be used for the treatment of tumours. |
Applicant(s) |
Merck Patent Gmbh |
Representative Drug(s) |
D02MMG |
Drug Info
|
IC50 = 120 nM |
[1] |
Patent ID |
WO2011006567 |
Title |
Aminopyridine Derivatives for Treating Tumors and Inflammatory Diseases. |
Abstract |
Compounds of the formula (I), wherein R1, R2, R3, R4, R7 and Y have the meanings specified in claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be used for treating tumors and for treating inflammatory diseases. |
Applicant(s) |
Merck Patent Gmbh |
Representative Drug(s) |
D06WAN |
Drug Info
|
IC50 = 0.1 to 10 nM |
[1] |
Patent ID |
WO2010127754 |
Title |
3-([1,2,3]Triazole-4-Yl)-Pyrrolo[2,3-B]Pyridine Derivates. |
Abstract |
The invention relates to compounds of the formula I, where R1, R2, and R3 have the meanings indicated in claim 1, wherein said compounds are inhibitors of PDK1 and cell proliferation/cell vitality, and can be used for treating tumors. |
Applicant(s) |
Merck Patent Gmbh |
Representative Drug(s) |
D0C6VX |
Drug Info
|
IC50 = 0.5 to 1000 nM |
[1] |
Patent ID |
WO2010120854 |
Title |
Chemical Compounds. |
Abstract |
The invention is directed to to substituted indazole derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1 - R6 and X are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically leukemia and cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention. |
Applicant(s) |
Glaxosmithkline Llc |
Representative Drug(s) |
D0PJ7M |
Drug Info
|
IC50 = 7.6 nM |
[1] |
Patent ID |
WO2010019637 |
Title |
Chemical Compounds. |
Abstract |
The invention is directed to pyrido[4,3-d]pyrimidin-5(6H)-one derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1, R2, R3, and R4 are defined below. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention. |
Applicant(s) |
Glaxosmithkline Llc |
Representative Drug(s) |
D0ZV9P |
Drug Info
|
IC50 = 3 to 10000 nM |
[1] |
Patent ID |
WO2010017047 |
Title |
Therapeutic Compounds. |
Abstract |
The present invention relates to pyrazolopyridines and imidazopyridines which are inhibitors of the kinase PDK1 and are thus useful for the treatment of myeloproliferative disorders or cancer. The compounds are also useful as inhibitors of other kinases such as FGFR3, NTRK3, RP-S6K and WEE1. Furthermore, the present compounds also selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. |
Applicant(s) |
Merck Sharp & Dohme Corp |
Representative Drug(s) |
D0I1YQ |
Drug Info
|
IC50 = 30000 nM |
[1] |
Patent ID |
WO2010007116 |
Title |
Pyridons As Pdk1 Inhibitors. |
Abstract |
The present invention encompasses compounds of general formula (1) while the groups R4 to R7 and the units W, L, Qa and QH are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use as medicaments having the above-mentioned properties. |
Applicant(s) |
Boehringer Ingelheim International Gmbh |
Representative Drug(s) |
D05GMT |
Drug Info
|
IC50 <= 1000 nM |
[1] |
Patent ID |
WO2010007114 |
Title |
Heterocyclyl Carbonic Acid Amides As Antiproliferative Agents, Pdkl Inhibitors. |
Abstract |
The present invention encompasses compounds of general formula (1) wherein the units W, A, L, Qa and QH are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use as medicaments having the above-mentioned properties. |
Applicant(s) |
Boehringer Ingelheim International Gmbh |
Representative Drug(s) |
D0P1VT |
Drug Info
|
IC50 <= 1000 nM |
[1] |
Patent ID |
WO2009153313 |
Title |
2 -Arylaminoquinazolines for Treating Proliferative Diseases. |
Abstract |
The invention provides novel compounds that are inhibitors of PDKI. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or composition. |
Applicant(s) |
Novartis Ag |
Representative Drug(s) |
D06LLS |
Drug Info
|
IC50 <= 50 nM |
[1] |
Patent ID |
WO2008109613 |
Title |
Benzo[C][2,7]Naphthyridine Derivatives, and Their Use As Kinase Inhibitors. |
Abstract |
The present invention relates to Benzo[c] [2,7] naph thy ri dine Derivatives of formula (I), compositions comprising an effective amount of a Benzo[c] [2,7]naphthyridine Derivative, methods for treating or preventing a proliferative disorder or an autoimmune disease, comprising administering to a subject in need thereof an effective amount of a Benzo[c] [2,7]naphthyridine Derivative, methods for modulating PDK-I activity, PKA activity, Akt activity, S6K activity, or PKC activity, comprising administering to a subject in need thereof an effective amount of a Benzo[c] [2,7] naphthyridine Derivative. The invention also relates to processes for preparing a Benzo[c] [2,7] naphthyridine Derivative. |
Applicant(s) |
WISSNER, Allan et al |
Representative Drug(s) |
D0IR8B |
Drug Info
|
IC50 = 8 nM |
[1] |
Patent ID |
WO2008109599 |
Title |
Pyrimido [5,4-C] Quinoline-2, 4-Diamine Derivatives and Methods of Use Thereof. |
Abstract |
The present invention relates to Pyrimxdo [5,4-c]quinoline-2, 4 -diamine Derivatives, compositions comprising an effective amount of a Pyrimido [5, 4 -c] quinoline-2, 4 -diamine Derivative of formula (I), methods for treating or preventing a proliferative disorder, comprising administering to a subject in need thereof an effective amount of an Pyrimido [ 5, 4 - c] quinoline-2, 4 -diamine Derivative. Disclosed are also methods for modulating PDK-I activity, comprising administering to a subject in need thereof an effective amount of a Pyrimido [5,4- c] quinoline- 2,4-diamine Derivative. The invention also relates to a process for preparing a Pyrimido [5,4- c] quinoline-2, 4 -diamine Derivative or a pharmaceutically acceptable salt thereof,. |
Applicant(s) |
WISSNER, Allan et al |
Representative Drug(s) |
D0U3IS |
Drug Info
|
IC50 = 8 nM |
[1] |
Patent ID |
WO2008107444 |
Title |
9H- Purine Derivatives and Their Use In The Treatment of Proliferative Diseases. |
Abstract |
The present invention encompasses compounds of general formula (1) wherein R1, R2 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties. |
Applicant(s) |
Boehringer Ingelheim International Gmbh |
Representative Drug(s) |
D0MI3E |
Drug Info
|
IC50 <= 1000 nM |
[1] |
Patent ID |
WO2008054238 |
Title |
Biologically Active Preparation (Variants) and A Method for The Production Thereof (Variants). |
Abstract |
The invention relates to medicine. The inventive biologically active preparation is embodied in the form of a liquid which is extracted from a biological raw material by breaking down a cellular structure and is treated by constant and low-frequency variable or pulsed fields. According to the first variant, the inventive method consists in freezing and thawing a raw material, in rapidly sublimating it at a temperature of 30-45, in condensing said raw material and in treating the thus obtained condensate by means of a combined constant field within a magnetic induction range of 0.01-100 mTl and by a low-frequency variable or pulsed field within the magnetic induction range of 0.01-100 mTl. According to the second variant, the inventive method consists in drying a raw material in vacuum by heating and in simultaneously treating it by a combined constant field within a magnetic induction range of 0.01-100 mTl and by a low-frequency variable or pulsed field within the magnetic induction range of 0.01-100 mTl. Volatile components are condensed on the walls of a closed space, the temperature of which is maintained within the range of dew-point temperatures. The condensate is obtained in the form of a biologically active liquid preparation, the rest being a solid biologically active preparation. |
Applicant(s) |
Kutushov Mikhail Vladimirovich |
Representative Drug(s) |
D0D5YE |
Drug Info
|
IC50 = 34 to 330 nM |
[1] |
Patent ID |
WO2008005457 |
Title |
Pyridinonyl Pdk1 Inhibitors. |
Abstract |
The present invention provides pyridinonyl PDKl inhibitors and methods of treating cancer using the same. |
Applicant(s) |
Sunesis Pharmaceuticals Biogen Idec Ma Inc |
Representative Drug(s) |
D08EGT |
Drug Info
|
IC50 < 500 nM |
[1] |
Patent ID |
WO2006015124 |
Title |
Fused Ring Heterocycle Kinase Modulators. |
Abstract |
The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity. |
Applicant(s) |
Sgx Pharmaceuticals, Inc |
Representative Drug(s) |
D0RP4U |
Drug Info
|
IC50 = 1000 to 5000 nM |
[1] |
Patent ID |
WO2003064397 |
Title |
Indazole Compounds Useful As Protein Kinase Inhibitors. |
Abstract |
The present invention provides compounds of formula (I), or a pharmaceutically acceptable derivative thereof, wherein R1, R2, V1, V2 and V3 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of AKT, PKA, PDK1, p70S6K, or ROCK kinase, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of utilizing those compositions in the treatment of various disorders. |
Applicant(s) |
Vertex Pharmaceuticals Incorporated |
Representative Drug(s) |
D0CK8H |
Drug Info
|
IC50 = 10 to 140 nM |
[1] |
Patent ID |
WO2011044157 |
Title |
Heterocyclic Compounds Useful As Pdk1 Inhibitors. |
Applicant(s) |
Sunesis & Biogen |
Representative Drug(s) |
D0CQ1M |
Drug Info
|
IC50 = 100 to 1000 nM |
[1] |
Patent ID |
WO2010065384 |
Title |
Drivs De 3-([1, 2, 3] Triazol-4-Yl)-Pyrrolo[2,3-B]Pyridine. |
Applicant(s) |
Merck & Co., Inc |
Representative Drug(s) |
D0RY6M |
Drug Info
|
IC50 <= 30000 nM |
[1] |
Patent ID |
WO2008079988 |
Title |
2-Arylaminoquinazolines for Treating Proliferative Diseases. |
Applicant(s) |
Novartis |
Representative Drug(s) |
D04UHW |
Drug Info
|
IC50 <= 50 nM |
[1] |
United States Patent and Trademark Office (USPTO) |
Patent ID |
US20130165450 |
Title |
Novel Thiazol-Carboximide Derivatives As Pdk1 Inhibitors. |
Applicant(s) |
Schering Corp |
Representative Drug(s) |
D0K8XT |
Drug Info
|
IC50 < 50 nM |
Click to Show More |
[1] |
2
|
D0Q8JK
|
Drug Info
|
IC50 = 100 nM
|
[1] |
3
|
D06LCB
|
Drug Info
|
IC50 < 250 nM
|
[1] |
4
|
D06PTW
|
Drug Info
|
IC50 < 250 nM
|
[1] |
5
|
D06WXJ
|
Drug Info
|
IC50 < 250 nM
|
[1] |
6
|
D07MSB
|
Drug Info
|
IC50 < 250 nM
|
[1] |
7
|
D08YPQ
|
Drug Info
|
IC50 < 250 nM
|
[1] |
8
|
D0H6AF
|
Drug Info
|
IC50 < 250 nM
|
[1] |
9
|
D0HP8K
|
Drug Info
|
IC50 < 250 nM
|
[1] |
10
|
D0PD2I
|
Drug Info
|
IC50 < 250 nM
|
[1] |
11
|
D0Q6RC
|
Drug Info
|
IC50 < 250 nM
|
[1] |
12
|
D0R3VG
|
Drug Info
|
IC50 < 250 nM
|
[1] |
13
|
D0U5HB
|
Drug Info
|
IC50 < 250 nM
|
[1] |
14
|
D0Z5HL
|
Drug Info
|
IC50 < 250 nM
|
[1] |
15
|
D0ZG0K
|
Drug Info
|
IC50 < 250 nM
|
[1] |
Patent ID |
US20130053382 |
Title |
Inhibitors of Phosphoinositide Dependent Kinase 1 (Pdk1). |
Representative Drug(s) |
D0SB4A |
Drug Info
|
IC50 = 33 nM |
Click to Show More |
[1] |
2
|
D07FMW
|
Drug Info
|
IC50 = 85 nM
|
[1] |
3
|
D0Y0RG
|
Drug Info
|
IC50 = 110 nM
|
[1] |
4
|
D07XBA
|
Drug Info
|
IC50 = 170 nM
|
[1] |
Patent ID |
US20120277229 |
Title |
Substituted 3-(1H-Benzo[D]Imidazol-2-Yl)-1H-Indazole Analogs As Inhibitors of The Pdk1 Kinase. |
Representative Drug(s) |
D09FQP |
Drug Info
|
IC50 = 140 nM |
Click to Show More |
[1] |
2
|
D06LSZ
|
Drug Info
|
IC50 = 160 nM
|
[1] |
3
|
D04EDM
|
Drug Info
|
IC50 = 280 nM
|
[1] |
4
|
D0RE3R
|
Drug Info
|
IC50 = 300 nM
|
[1] |
5
|
D07ZKE
|
Drug Info
|
IC50 = 780 nM
|
[1] |
Patent ID |
US20120208819 |
Title |
Heterocyclic Compounds Useful As Pdk1 Inhibitors. |
Representative Drug(s) |
D05OTD |
Drug Info
|
IC50 = 100 to 5000 nM |
Click to Show More |
[1] |
2
|
D07HOA
|
Drug Info
|
IC50 = 100 to 5000 nM
|
[1] |
3
|
D07IQE
|
Drug Info
|
IC50 = 100 to 5000 nM
|
[1] |
4
|
D09BNP
|
Drug Info
|
IC50 = 100 to 5000 nM
|
[1] |
5
|
D0AM2D
|
Drug Info
|
IC50 = 100 to 5000 nM
|
[1] |
6
|
D0D0ML
|
Drug Info
|
IC50 = 100 to 5000 nM
|
[1] |
7
|
D0J9DI
|
Drug Info
|
IC50 = 100 to 5000 nM
|
[1] |
8
|
D0W3JC
|
Drug Info
|
IC50 = 100 to 5000 nM
|
[1] |
Patent ID |
US20140017701 |
Title |
Chimeric Pdk1 Kinases. |
Applicant(s) |
Biondi Rm, Laura Al, Lopez G, et Al |
Patent ID |
US20130245355 |
Title |
3-Hetaryl-Substituted Pyrrolo [2,3B] Pyridine Derivatives As Pdk1 Inhibitors. |
Applicant(s) |
Merck Patent Gmbh |
Patent ID |
US20090111799 |
Title |
Anti-Infective Agents Against Intracellular Pathogens. |
Applicant(s) |
The Ohio State University Research Foundation |
Representative Drug(s) |
D00MLJ |
Drug Info
|
IC50 = 2000 nM |
[1] |
Patent ID |
US20070135429 |
Title |
10,11-Dimethoxydibenzo[C,F]-2,7-Naphthyridin-6-Amine; Inhibiting Pyruvate Dehydrogenase Kinase Pdk-1In A Cell; Antiproliferative Agent; Brain, Colon Cancer, Leukemia, Prostate and Breast Cancer. |
Applicant(s) |
Wyeth |
Representative Drug(s) |
D0I5KI |
Drug Info
|
IC50 = 60 to 7500 nM |
[1] |
Patent ID |
US200607105563 |
Title |
5-Ureido-3-[(4-(3-Methoxyphenyl) Pyrrol-2-Yl)Methylene]Indolin-2-One and Derivatives; Inhibition of Phosphoinositide-Dependent Kinase-1 (Pdk-1). |
Applicant(s) |
Schering Ag |
Representative Drug(s) |
D0ZE5U |
Drug Info
|
IC50 = 520 nM |
[1] |
Patent ID |
US20120003668 |
Title |
High Resolution Complex Structure and Allosteric Effects of Low Molecular Weight Activators On The Protein Kinase Pdk1. |
Applicant(s) |
Universities Des Saarlandes |
European Patent Office (EPO) |
Patent ID |
EP20041486488 |
Title |
Use of A Compound of formula I for Making A Pharmaceutical Composition. |
Applicant(s) |
Phosphosites Gmbh |
Representative Drug(s) |
D0YD1Q |
Drug Info
|
IC50 = 20000 nM |
[1] |